Curnutte John T 4

What Happened

• John T. Curnutte, a director of Pliant Therapeutics, was granted a derivative award covering 70,000 shares on June 11, 2026. The reported acquisition price is $0.00, and the grant is reported as a derivative security (transaction code A — award/grant).

Key Details

• Transaction date: 2026-06-11; Filing date: 2026-06-12 (timely).
• Shares involved: 70,000 underlying shares; reported acquisition price $0.00 (total cash paid reported $0).
• Vesting: 25% of the option vests and becomes exercisable on each of Oct 1, 2026; Jan 1, 2027; and Apr 1, 2027. The remaining 25% vests on the earlier of (i) the one‑year anniversary of the June 11, 2026 grant or (ii) the next annual meeting of stockholders, subject to continued service as a director (see footnote F1).
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Filing punctuality: Filed the next day (appears timely); no late-filing indication in the excerpt.

Context

• This was an awards/derivative grant rather than an open-market purchase or sale. Such grants are commonly used for director compensation; they do not itself indicate buying or selling sentiment until/if exercised or sold.
• Because the grant is a derivative (option-like) with a vesting schedule, the shares only become exercisable/issuable over time and are contingent on continued service per the stated schedule.